Liposomal Doxorubicin Market by Product, by Application. by End-User, and By Region

The global liposomal doxorubicin market size was estimated to be USD 1.34 billion in 2023 and is expected to reach USD 2.43 billion by 2034 with a CAGR of 6.06% during the forecast period 2024-2034. Increasing incidence of cancer, advancements in drug delivery technology, reduced side effects, clinical advancements and research, growing awareness and patient advocacy, rising technological advancements, and strategic collaborations and partnerships will drive the market growth.

A key factor propelling the liposomal doxorubicin industry is the increasing incidence of cancer, including ovarian, breast, and Kaposi's sarcoma. Globally rising cancer rates will probably result in a greater need for chemotherapy medications such as liposomal doxorubicin. For instance, Johnson & Johnson strengthened their market exclusivity in November 2022 when they received patent extensions for Doxil/Caelyx in many countries.

By product, the J&J (Doxil/Caelyx) segment accounted for the highest revenue-grossing segment in the global liposomal doxorubicin market in 2023 owing to the superior therapeutic benefits, reduced side effects, and extensive clinical validation of liposomal doxorubicin, reaffirming J&J's commitment to advancing cancer care. For instance, Sun Pharmaceutical Industries Ltd. introduced ONCODOX PEGil, a pegylated liposomal doxorubicin injection, in India in August 2023. Additionally, the sun pharma (Lipodox)segment is predicted to grow at the fastest CAGR during the forecast period owing to the company's focus on expanding its market presence, continuous research and development efforts, and the increasing adoption of Lipodox as an effective and affordable alternative in cancer treatment.

By application, the ovarian cancer segment accounted for the highest revenue-grossing segment in the global liposomal doxorubicin market in 2023 owing to the increased prevalence of ovarian cancer, coupled with the effectiveness of liposomal doxorubicin in treating this specific cancer type. For instance, Fresenius Kabi AG stated in October 2023 that it will increase its capacity to produce liposomal doxorubicin in response to growing demand. Additionally, the breast cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing incidence of breast cancer worldwide, increased adoption of advanced therapies, and the proven efficacy of liposomal doxorubicin in the treatment of breast cancer.

By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global liposomal doxorubicin market in 2023 owing to the increased demand for cancer treatment services and the predominant role of hospitals and clinics as primary healthcare providers. For instance, Teva Pharmaceutical Industries Ltd. introduced a competitively priced generic version of liposomal doxorubicin onto the European market in December 2022. Additionally, the cancer research centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing emphasis on cutting-edge research, clinical trials, and collaborative efforts in advancing cancer treatment.

North American region is anticipated to have the highest revenue share during the forecast period owing to the region's well-established healthcare infrastructure, a high prevalence of cancer cases, and a robust regulatory framework promoting the adoption of advanced cancer therapies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing healthcare infrastructure development, rising prevalence of cancer, and a growing focus on adopting advanced cancer treatment modalities. For instance, in October 2023, CSPC Pharmaceutical Group Limited introduced liposomal doxorubicin in China to cater to the country's sizable home market.

This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Product, Application, and End-User
• Market Forecast for 5 Regions and 17+ Countries
• North America (U.S. and Canada)
• Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
• MEA (South Africa, GCC, Rest of MEA)
• Exhaustive Company Profiles of the Top 10+ Major Market Players
• 20% Free Customization Available to Meet Your Exact Requirement.

Segmentation: Liposomal Doxorubicin Market Report 2023 - 2034

Liposomal Doxorubicin Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)

• J&J (Doxil/Caelyx)
• Sun Pharma (Lipodox)
• Teva (Myocet)
• Others

Liposomal Doxorubicin Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)

• Ovarian cancer
• Breast cancer
• Kaposi sarcoma
• Other applications

Liposomal Doxorubicin Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)

• Hospitals and Clinics
• Cancer Research Centers
• Others

Liposomal Doxorubicin Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA